A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Clinical trial NCT04733417 · UNKNOWN
Trial details
- NCT number
- NCT04733417
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-26
- Primary completion
- 2022-08-30
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.